This informal CPD article ‘Risk‑Based Quality Management in 2026’ was provided by Triumph Research Intelligence, an organisation supporting Risk-Based Quality Management (RBQM) to drive better clinical trials, improved patient safety, and compliance with Good Clinical Practice (GCP).
If you work in clinical development, there is a good chance Risk‑Based Quality Management (RBQM) has already featured in your 2026 resolutions. Maybe you promised yourself: “This is the year we move beyond pilots,” or “This is the year we finally align with ICH E6(R3) without drowning the teams in more process.” The real test now is not whether you have an RBQM slide in your governance deck, but whether risk really shapes day‑to‑day decisions across your trials.
Why 2026 Is a Line in the Sand
2026 is the year E6(R3) moves from horizon to reality, and with it, a clear expectation that quality is designed in, proportionate, and risk‑based (1,2,). Regulators are now asking how you decide what to monitor, why, and how you know your approach actually works (2,3).
For clinical teams, this means two uncomfortable truths:
- First, a risk‑based framework on paper, without the technology and habits to support it, is no longer enough. A framework without real‑time data, centralized monitoring, and a feedback loop quickly becomes a tidy diagram that lives in a PDF rather than in the study room. (1,2,3).
- Second, partial RBQM adoption, a risk assessment here, a dashboard there, is increasingly visible to regulators and partners as a gap, not progress. Industry assessments suggest that RBQM components are implemented in only a little over half of trials, with lower adoption during execution and clear barriers around awareness, skills, and change management (4).
Before You Move Another Inch
Before you sign off on any new RBQM workplan for 2026, it is worth asking some straight questions. Do you know where risk really lives in your studies, or only where your templates tell you it should live? Many organizations still treat risk assessment as a one‑off start‑up exercise rather than a living view anchored in true Critical‑to‑Quality factors and refreshed as the trial learns (1,2).
Are your central monitoring activities genuinely proportionate and data‑driven, or just rebranded routine listings review? Centralized monitoring is meant to pick up patterns, trends and outliers that would otherwise go unnoticed, using statistics and visualisation to direct attention (1,2,3).
And perhaps toughest: when issues emerge, can you clearly trace how risk signals triggered action, what was done, and whether it worked? Guidance from agencies now calls for formal, documented processes that connect central signals, investigation, escalation, and resolution (2,3,).
Making the First Moves
The temptation in 2026 is to respond to E6(R3) with more workshops, more SOPs, more training. Those matter, but they are not your first moves. Your first moves should be small, specific and brutally practical.
Start with one or two studies where the stakes are high enough that better risk visibility will clearly matter, for example:
- Complex, multi‑country late‑phase trials (3,5).
- High‑risk early‑phase work (3,5).
On those studies, make three commitments:
- The risk assessment will be truly cross‑functional, grounded in Critical‑to‑Quality factors, and revisited as the trial evolves (1,2).
- The central monitoring plan will be more than a list of listings, explicitly linking key risks, indicators, and quality tolerance limits to monitoring activities (1,2,3).
- Every meaningful signal will be tracked through to closure, with a documented chain from detection to action and outcome (3,5).
Focus on creating a single, coherent story of risk and action, so that the connection between signal, investigation, decision and outcome is visible end‑to‑end.
RBQM goals for 2026
The Hard Part Nobody Wants to Admit
If RBQM were just about good ideas and better stats, the industry would have finished the job years ago. The friction is human. Shifting from “we check everything, just in case” to “we focus on what matters most” can feel risky to monitors, clinicians and statisticians who built careers on thoroughness (4,5).
Organizations that are making RBQM stick tend to do a few things differently:
- They are honest about trade‑offs: you cannot do everything with the same intensity, so you choose deliberately and document why, in line with risk‑proportionate expectations in E6(R3) (2).
- They invest in role‑specific coaching, not just generic RBQM training, helping a CRA, a data manager, or a medical monitor understand exactly how their decisions change in a risk‑based model (4,5).
- They design workflows and dashboards that make new behaviours easier, not harder, enabling central reviewers to interpret risk signals and escalate issues efficiently (3).
- They ensure ownership of actions is transparent, reducing ambiguity and friction and supporting traceability during inspections (3).
Turning 2026 Resolutions into a Different Kind of Year
So what does “from resolution to action” really look like over the next twelve months? It looks like elevating E6(R3) to a concrete design principle, not a theoretical reference, by explicitly tying design, controls and oversight to Critical‑to‑Quality factors and anticipated risks (1,2). It looks like choosing a small number of pathfinder trials, giving them serious RBQM treatment, and using what you learn to shape portfolio‑wide standards (4,5).
And it looks like backing that intent with the right processes, tools and behaviours, not necessarily more complexity, so that centralized monitoring, risk review, and documented decision‑making become routine rather than exceptional (2,3,5).
If your organisation has set RBQM goals for 2026, the most valuable step you can take now is to map where you are against where E6(R3) and modern practice say you need to be and then decide which gaps you want to close first (2,4,5). Because in 2026, the question is no longer whether you have an RBQM strategy. It is whether your trials, your teams and your data can prove it (2,3,5).
We hope this article was helpful. For more information from Triumph Research Intelligence, please visit their CPD Member Directory page. Alternatively, you can go to the CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.
REFERENCES
(1) International Council for Harmonisation. Guideline for Good Clinical Practice E6(R3): Step 4 final guideline, 6 January 2025.
URL: https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf
(2) European Medicines Agency. ICH E6(R3) Guideline on good clinical practice (GCP), Step 5 version.
URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf
(3) Medicines and Healthcare products Regulatory Agency. Oversight and monitoring of investigational medical product trials: guidance on monitoring activities, including central monitoring and escalation, 2022.
URL: https://www.gov.uk/government/publications/oversight-and-monitoring-of-investigational-medical-product-trials/oversight-and-monitoring-activities
(4) Getz K et al. Comprehensive Assessment of Risk-Based Quality Management (RBQM) Adoption. Therapeutic Innovation & Regulatory Science, 2024.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11043178/
(5) ICON plc. How GCP Updates Make Way for an RBQM Revolution, 2025.
URL: https://www.iconplc.com/insights/blog/2025/08/11/how-gcp-updates-make-way-rbqm-revolution
